IDH2 mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapy

By afschroeder • November 6, 2025

Hoff FW, Huang Y, Welkie RL, Swords RT, Traer E, Stein EM, Lin TL, Baer MR, Duong VH, Blum WG, Arellano ML, Stock W, Odenike O, Zeidner JF, Olin RL, Smith CC, Schiller GJ, Curran EK, Handa SV, Heerema NA, Chen T, Martycz M, Stefanos M, Marcus SG, Rosenberg L, Druker BJ, Levine RL, Burd A, Yocum AO, Borate UM, Mims AS, Byrd JC, Madanat YF. IDH2 mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapy. Haematologica. 2025 Nov 6. doi: 10.3324/haematol.2025.288743. Epub ahead of print. PMID: 41195510.

Tags: Hematology/Oncology, Publications

Related Posts

p16INK4a and DNA methylation clocks in women treated with chemotherapy for early breast cancer

Muss HB, Sun C, Ding YC, Ji J, White TA, Nyrop K, LeBrasseur NK, Neuhausen SL, Mitin N, Sedrak MS. p16INK4a and DNA methylation clocks in[...]

Young Women With Pancreatic Cancer: A High-Risk Group for Demoralization

Levi A, Nasr A, Cui Y, Abbas AA, Arouchian TT, Coveler AL, Pierce TL, Anderson BT, Collisson E, Davelaar J, Lo SK, Gaddam S, Gong[...]

Perioperative durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable gastric and gastro-oesophageal junction adenocarcinoma (MATTERHORN): final results of overall survival and event-free survival by pathological response in a global, randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

Janjigian YY, Al-Batran SE, Wainberg ZA, Muro K, Molena D, Van Cutsem E, Hyung WJ, Wyrwicz L, Oh DY, Omori T, Moehler M, Bragagnoli AC,[...]